JENNER VACCINE FOUNDATION
The aims of the Foundation are to undertake research and development aimed at the creation, testing and deployment of new vaccines against diseases of humans and livestock. The Foundation will have a particular focus on vaccines of the developing world where greatest needs exist for novel vaccines.
Financial health, per its FY2025 accounts
The accounts state that the Foundation reported a net surplus of £11,354 for the period ended 31 July 2025, driven by investment gains. Per the trustees' report, the charity operates on a low-cost basis with minimal administrative expenditure and holds unrestricted reserves of £457,771, which the trustees consider sufficient to manage timing fluctuations without undue financial risk.
What the accounts disclose
“It is the policy of the Board that the balance on unrestricted funds is maintained at such a level as is deemed sufficient to enable the Foundation to accommodate fluctuations in the timing of receipts and payments without exposing the Foundation to undue financial risk.” — page 7
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
Trustees
- Dr Bryan Charleston
- Dr Michael James Francis
- PROFESSOR DAVID MAXWELL SALISBURY
- Professor Gavin Robert Screaton
- Professor Helen Alison Fletcher
- Professor Sir Andrew Pollard FRS
- Professor Venugopal Nair
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/07/2025 | £31k | £57k |
| 31/03/2024 | £21k | £45k |
| 31/03/2023 | £15k | £43k |
| 31/03/2022 | £14k | £35k |
| 31/03/2021 | £10k | £20k |
Common questions
Is JENNER VACCINE FOUNDATION financially healthy?
Per its FY2025 accounts: The accounts state that the Foundation reported a net surplus of £11,354 for the period ended 31 July 2025, driven by investment gains. Per the trustees' report, the charity operates on a low-cost basis with minimal administrative expenditure and holds unrestricted reserves of £457,771, which the trustees consider sufficient to manage timing fluctuations without undue financial risk. Its FY2025 accounts were audited by Gravita Audit Oxford LLP.